Unraveling the relationships between alpha- and beta-adrenergic modulation and the risk of heart failure

Baudier, Claire and Fougerousse, Françoise and Asselbergs, Folkert W. and Guedj, Mickael and Komajda, Michel and Kotecha, Dipak and Thomas Lumbers, R. and Schmidt, Amand F. and Tyl, Benoît (2023) Unraveling the relationships between alpha- and beta-adrenergic modulation and the risk of heart failure. Frontiers in Cardiovascular Medicine, 10. ISSN 2297-055X

[thumbnail of pubmed-zip/versions/2/package-entries/fcvm-10-1148931-r1/fcvm-10-1148931.pdf] Text
pubmed-zip/versions/2/package-entries/fcvm-10-1148931-r1/fcvm-10-1148931.pdf - Published Version

Download (1MB)

Abstract

Background: The effects of α and ß adrenergic receptor modulation on the risk of developing heart failure (HF) remains uncertain due to a lack of randomized controlled trials. This study aimed to estimate the effects of α and ß adrenergic receptors modulation on the risk of HF and to provide proof of principle for genetic target validation studies in HF.

Methods: Genetic variants within the cis regions encoding the adrenergic receptors α1A, α2B, ß1, and ß2 associated with blood pressure in a 757,601-participant genome-wide association study (GWAS) were selected as instruments to perform a drug target Mendelian randomization study. Effects of these variants on HF risk were derived from the HERMES GWAS (542,362 controls; 40,805 HF cases).

Results: Lower α1A or ß1 activity was associated with reduced HF risk: odds ratio (OR) 0.83 (95% CI 0.74–0.93, P = 0.001) and 0.95 (95% CI 0.93–0.97, P = 8 × 10−6). Conversely, lower α2B activity was associated with increased HF risk: OR 1.09 (95% CI 1.05–1.12, P = 3 × 10−7). No evidence of an effect of lower ß2 activity on HF risk was found: OR 0.99 (95% CI 0.92–1.07, P = 0.95). Complementary analyses showed that these effects were consistent with those on left ventricular dimensions and acted independently of any potential effect on coronary artery disease.

Conclusions: This study provides genetic evidence that α1A or ß1 receptor inhibition will likely decrease HF risk, while lower α2B activity may increase this risk. Genetic variant analysis can assist with drug development for HF prevention.

Item Type: Article
Subjects: Archive Paper Guardians > Medical Science
Depositing User: Unnamed user with email support@archive.paperguardians.com
Date Deposited: 02 Nov 2023 10:11
Last Modified: 02 Nov 2023 10:11
URI: http://archives.articleproms.com/id/eprint/2085

Actions (login required)

View Item
View Item